A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.

PHASE2CompletedINTERVENTIONAL
Enrollment

163

Participants

Timeline

Start Date

March 20, 2019

Primary Completion Date

October 13, 2020

Study Completion Date

October 13, 2020

Conditions
Rheumatoid Arthritis
Interventions
DRUG

SKI-O-703

Oral administration, twice per day

DRUG

Placebo

Oral administration, twice per day

Trial Locations (40)

4107

Oscotec Investigational Site (Site 2502), Kyiv

16635

Oscotec Investigational Site (Site 3107), Duncansville

21009

Oscotec Investigational Site (Site 2509), Vinnytsia

21018

Oscotec Investigational Site (Site 2506), Vinnytsia

21029

Oscotec Investigational Site (Site 2504), Vinnytsia

33014

Oscotec Investigational (Site 3104), Miami Lakes

33614

Oscotec Investigational Site (Site 3112), Tampa

36024

Oscotec Investigational Site (Site 2507), Poltava

40504

Oscotec Investigational Site (Site 3108), Lexington

46002

Oscotec Investigational Site (Site 2505), Ternopil

61058

Oscotec Investigational Site (Site 2508), Kharkiv

73103

Oscotec Investigational Site (Site 3102), Oklahoma City

75010

Oscotec Investigational Site (3106), Carrollton

75150

Oscotec Investigational Site (Site 3109), Mesquite

76018

Oscotec Investigational Site (Site 2510), Ivano-Frankivsk

77034

Oscotec Investigational Site (Site 3111), Houston

77375

Oscotec Investigational Site (Site 3101), Tomball

78229

Oscotec Investigational Site (Site 3103), San Antonio

90211

Oscotec Investigational Site (Site 3110), Beverly Hills

91786

Oscotec Investigational Site (Site 3105), Upland

119049

Oscotec Investigational Site (Site 2304), Moscow

129110

Oscotec Investigational Site (Site 2305), Moscow

194291

Oscotec Investigational Site (Site 2302), Saint Petersburg

196084

Oscotec Investigational Site (Site 2303), Saint Petersburg

390026

Oscotec Investigational Site (Site 2306), Ryazan

630099

Oscotec Investigational Site (Site 2308), Novosibirsk

634050

Oscotec Investigational Site (Site 2301), Tomsk

650066

Oscotec Investigational Site (Site 2307), Kemerovo

702 00

Oscotec Investigational Site (Site 2101), Ostrava

760 01

Oscotec Investigational Site (Site 2102), Zlín

61-397

Oscotec Investigational Site (Site 2203), Poznan

85-168

Oscotec Investigational Site (Site 2204), Bydgoszcz

53-224

Oscotec Investigational Site (Site 2208), Wroclaw

20-582

Oscotec Investigational Site (Site 2207), Lublin

01-518

Oscotec Investigational Site (Site 2202), Warsaw

15-879

Oscotec Investigational Site (Site 2201), Bialystok

05-830

Oscotec Investigational Site (Site 2206), Nadarzyn

27-400

Oscotec Investigational Site (Site 2209), Ostrowiec Świętokrzyski

01023

Oscotec Investigational Site (Site 2501), Kyiv

04050

Oscotec Investigational Site (Site 2503), Kyiv

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Oscotec Inc.

INDUSTRY

NCT04057118 - A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies. | Biotech Hunter | Biotech Hunter